Updated 7/18/2019. Based on attendance or presentation at prior events, here is a list of potential events for Resverlogix in the year of the big news. There is no guarantee that Resverlogix will present at all of the events listed below. Did I miss any? If so, let me know! Archived 2019 events are at the bottom of this message.

Q3 2019:

European Society of Cardiology (ESC) August 31 to Sept 4, 2019; Paris, France. There are two regular abstracts listed for apabetalone or BETonMACE to be presented at ESC 2019 as well as a Resverlogix sponsored symposium. Only poster titles are available right now. 

Sat August 31, 2019 Symposium "Epigenetics: A new pathway to tackle residual risk?" See here and here. 

Mon Sept 2, 2019, 14:00: BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

Tues Sept 3, 2019, 08:30: Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

European Association for the Study of Diabetes (EASD): Sept 16-20, 2019; Barcelona, Spain. There is a poster presentation on September 17th, 2019 entitled "Apabetalone modulates Th1 responses in diabetes and CVD through intrinsic and extrinsic mechanisms: in vitro and in human studies." See abstract here.

Q4 2019:

Clinical Trials on Alzheimer's Disease/Asia (CTAD Asia): October 11-12, 2019; Beijing, China

American Society for Nephrology (ASN) Kidney Week: Nov 5-10, 2019; Washington, D.C.

BIO-Europe: Nov 11-13, 2019

American Heart Association (AHA): November 16-18, 2019; Philadelphia, PA

Clinical Trials on Alzheimer's Disease (CTAD): December 4-7, 2019; San Diego, CA

Past 2019 events:

Biotech Showcase January 7-9, 2019; San Francisco, CA. See here for slide deck.

BIO CEO & Investor Conference February 11-12, 2019; New York, NY. See here for slide deck.

American College Cardiology (ACC) March 16-18, 2019; New Orleans, LA. BETonMACE cognition sub-study poster here; Vascular Inflammation and Cellular Adhesion poster here.

Roth Conference March 17-19, 2019; Orange County, CA. Webcast in advance of conference here and accessible until mid-April. Slide deck for webcast similar to the one below for BIO-Europe.

BIO-Europe Spring March 25-27, 2019; Vienna, Austria. See here for slide deck.

14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2019): March 26-31, 2019; Lisbon, Portugal. See abstracts here. Endothelial and Microglial Cell Activation poster here. Dr. Cumming's BETonMACE cognition sub-study presentation here.

Vascular Discovery 2019: From Genes to Medicine (Formerly ATVB:PVD): May 14-16, 2019; Boston, MA. Resverlogix had two presentations. Apabetalone (RVX-208) Inhibits Key Pro-Atherogenic Mediators and Pathways in Diabetes and Inflammatory Conditions; in vitro and in Patients (Abstract here; poster here). Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients (Abstract here; poster here).

European Atherosclerosis Society (EAS) May 26-29, 2019; Maastricht, Netherlands. Norman Wong presented a poster titled "APABETALONE (RVX-208) ATTENUATES INFLAMMATORY MILIEU UNDERLYING ADHESION OF MONOCYTES TO ENDOTHELIAL CELLS IN TYPE 2 DIABETES MELLITUS WITH CARDIOVASCULAR DISEASE PATIENTS." Abstract available here; poster here.

Gordon Research Conference: Epigenetic Regulation of Cardiovascular Disease: May 26-31, 2019; Hong Kong, China. Dr. Norman Wong is on the schedule for Thursday afternoon May 30th in the Epigenetic Therapies for Cardiovascular Disease section with a presentation entitled "Epigenetic Modifying Therapy for Cardiovascular Disease that Targets BET Proteins." Slides/presentation not posted.

American Diabetes Association (ADA) June 7-11, 2019; San Francisco, CA. Resverlogix presented a poster on Monday June 10th. "474-P - Apabetalone (RVX-208) Attenuates an Inflammatory Milieu that Enhances Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Disease Patients." Abstract here; poster here.

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA): June 13-16, 2019; Budapest, Hungary. Dr. Kulikowski delivered an oral presenation on Friday June 14th titled: "Apabetalone, an Inhibitor of BET Proteins, Improves Cardiovascular Risk and Reduces Alkaline Phosphatase in both CVD Patients and Primary Human Cell Culture Systems." Dr. Kalantar-Zadeh presented a poster on June 14th titled: "Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients." Abstract here; poster here. There was also a Resverlogix sponsored symposium on Saturday June 15th "Vascular calcification in kidney disease: Epigenetics as a novel approach?" See agenda here and slides here. Full presentations will eventually be posted here.

2019 FSHD Society International Research Congress June 19-20, 2019; Marseille, France. Dr. Christopher Sarsons, Applied Research Scientist, Resverlogix, delivered an oral presentation: "Apabetalone, a CVD Phase 3 Clinical-stage BET Inhibitor, Opposes DUX4 Expression in Primary Human FSHD Muscle Cells." The abstract for this presentation S5.5 can be found in the conference abstract book here. 

Alzheimer's Association International Conference (AAIC) July 14-18, 2019; Los Angeles, CA. Dr. Jeffrey Cummings presented a poster on July 14th titled "Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease." See poster here.